Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab enema pilot study in active left-sided ulcerative colitis
2007-007702-30Phase 2Completed
- Sponsor
- Cosmo Pharmaceuticals
- Start
- Jul 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of infliximab in autoimmune colitis, sponsored by Cosmo Pharmaceuticals. Primary endpoints: Clinical remission at 6 weeks and Safety and tolerability. Started Jul 2008; status: completed.
02
Drugs
infliximab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2007-007702-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007702-30.